贝伐珠单抗联合大分割立体定向再照射治疗复发高级别胶质瘤的多中心Ⅰ期剂量递增研究
该多中心Ⅰ期剂量递增研究评估贝伐珠单抗联合3次大分割立体定向再照射治疗复发高级别胶质瘤的最大耐受剂量。采用标准3+3设计,从9 Gy×3起始,11 Gy×3队列出现1例剂量限制性毒性(3级乏力与认知恶化),被确定为最大耐受剂量。意向治疗中位总生存期为13个月,提示该方案可行且耐受性尚可。
要点
- 贝伐珠单抗联合3次大分割立体定向再照射的最大耐受剂量为11 Gy×3。
- 11 Gy×3队列出现1例剂量限制性毒性:3级乏力与认知恶化。
- 意向治疗中位总生存期为13个月,未观察到症状性放射性坏死。
核心结论
- 贝伐珠单抗联合3次大分割立体定向再照射治疗复发高级别胶质瘤可行且耐受性尚可,最大耐受剂量为11 Gy×3,意向治疗中位总生存期为13个月。
研究设计与样本
- 多中心Ⅰ期剂量递增研究,采用标准3+3设计,纳入复发高级别胶质瘤且Karnofsky功能状态评分≥60、既往接受标准分次初始放疗、复发肿瘤体积≤40 cm3、无脑干或胼胝体受累的患者。
主要发现
- 9 Gy×3队列入组3例,10 Gy×3队列入组5例,11 Gy×3队列入组7例。
- 11 Gy×3队列出现1例剂量限制性毒性,为3级乏力与认知恶化,可能与大分割立体定向再照射相关。
- 未观察到症状性放射性坏死,但切除标本中可见明显的治疗相关效应和坏死。
- 意向治疗中位总生存期为13个月。
关键数值与推荐
- 贝伐珠单抗剂量为10 mg/kg,每2周一次;完成2次贝伐珠单抗后开始大分割立体定向再照射,每2天一次,共3次,起始剂量为9 Gy/次。
- 剂量限制性毒性定义为任何可能、很可能或肯定与放疗相关的3至5级毒性。
- 11 Gy×3被确定为与贝伐珠单抗联合的最大耐受剂量。
临床怎么用
- 对于符合条件的复发高级别胶质瘤患者,可考虑贝伐珠单抗联合3次大分割立体定向再照射,最大耐受剂量为11 Gy×3。
- 治疗期间需关注乏力与认知恶化等可能相关的毒性。
局限性
- 本研究为Ⅰ期剂量递增研究,样本量小,主要目的是确定最大耐受剂量,疗效结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To establish the maximum tolerated dose of a 3-fraction hypofractionated stereotactic reirradiation schedule when delivered with concomitant bevacizumab to treat recurrent high-grade gliomas. METHODS AND MATERIALS: Patients with recurrent high-grade glioma with Karnofsky performance status ≥60, history of standard fractionated initial radiation, tumor volume at recurrence ≤40 cm3, and absence of brainstem or corpus callosum involvement were eligible. A standard 3+3 phase 1 dose escalation trial design was utilized, with dose-limiting toxicities defined as any grade 3 to 5 toxicities possibly, probably, or definitely related to radiation. Bevacizumab was given at a dose of 10 mg/kg every 2 weeks. Hypofractionated stereotactic reirradiation was initiated after 2 bevacizumab doses, delivered in 3 fractions every other day, starting at 9 Gy per fraction. RESULTS: A total of 3 patients were enrolled at the 9 Gy × 3 dose level cohort, 5 in the 10 Gy × 3 cohort, and 7 in the 11 Gy × 3 cohort. One dose-limiting toxicity of grade 3 fatigue and cognitive deterioration possibly related to hypofractionated stereotactic reirradiation was observed in the 11 Gy × 3 cohort, and this dose was declared the maximum tolerated dose in combination with bevacizumab. Although no symptomatic radionecrosis was observed, substantial treatment-related effects and necrosis were observed in resected specimens. The intent-to-treat median overall survival was 13 months. CONCLUSIONS: Reirradiation using a 3-fraction schedule with bevacizumab support is feasible and reasonably well tolerated. Dose-escalation was possible up to 11 Gy × 3, which achieves a near doubling in the delivered biological equivalent dose to normal brain, in comparison with our previous 6 Gy × 5 schedule. Promising overall survival warrants further investigation.
引用
- Clarke J, Neil E, Terziev R, et al. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2017. PMID: 28870792. doi:10.1016/j.ijrobp.2017.06.2466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。